ABSTRACT
No disponible
Subject(s)
Humans , Coronavirus Infections/drug therapy , Bronchodilator Agents/administration & dosage , Pulmonary Disease, Chronic Obstructive/drug therapy , Severe Acute Respiratory Syndrome/epidemiology , Severe acute respiratory syndrome-related coronavirus/pathogenicity , Protective Factors , Coronavirus Infections/physiopathology , Pulmonary Disease, Chronic Obstructive/complicationsABSTRACT
WHAT IS KNOWN AND OBJECTIVE: Beta-lactam antibiotic (BLA) therapy is frequently needed to treat infective endocarditis (IE). Hypersensitive reactions to BLA restrict BLA therapy in allergic patients. In the current case, we aim to describe the utility of desensitization (DS) in this context. Although the evidence is limited, DS is recommended. CASE DESCRIPTION: This case report deals with a 79-year-old woman with a clinical suspicion of allergy to BLA and a methicillin-sensitive Staphylococcus aureus (MSSA) IE. A cloxacillin DS protocol was developed to enable treatment with cloxacillin. WHAT IS NEW AND CONCLUSION: Alternative antibiotic treatments may be less effective or not available in MSSA IE. In this case report, DS allowed optimal cloxacillin treatment.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Cloxacillin/administration & dosage , Endocarditis, Bacterial/drug therapy , Staphylococcal Infections/drug therapy , Aged , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/immunology , Cloxacillin/adverse effects , Cloxacillin/immunology , Desensitization, Immunologic/methods , Drug Hypersensitivity/immunology , Endocarditis, Bacterial/microbiology , Female , Humans , Penicillins/adverse effects , Penicillins/immunology , Sepsis/drug therapy , Staphylococcal Infections/microbiology , Staphylococcus aureus/isolation & purificationABSTRACT
WHAT IS KNOWN AND OBJECTIVE: Abiraterone acetate (AA) is an androgen receptor axis inhibitor, indicated together with prednisone, for metastatic castration-resistant prostate cancer. Withdrawal syndrome for classical antiandrogen treatments is well known, but not so known for AA. Abiraterone withdrawal syndrome (AWS) could be related to simultaneous prednisone discontinuation or to an androgenic effect of AA metabolites. CASE DESCRIPTION: A case is described of a patient with long-term AWS without prednisone discontinuation. The clinical and prostate-specific antigen (PSA) response allowed an 8-month delay in docetaxel treatment. WHAT IS NEW AND CONCLUSION: Prednisone did not play a role in AWS in this case. The long-term response allowed a delay in future treatment.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Substance Withdrawal Syndrome/etiology , Abiraterone Acetate/administration & dosage , Abiraterone Acetate/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Docetaxel/administration & dosage , Docetaxel/adverse effects , Humans , Male , Prednisone/administration & dosage , Prednisone/adverse effects , Prostate-Specific Antigen/metabolism , Prostatic Neoplasms, Castration-Resistant/drug therapy , Prostatic Neoplasms, Castration-Resistant/metabolism , Treatment OutcomeABSTRACT
WHAT IS KNOWN AND OBJECTIVE: Unexplained thrombocytopenia is a common clinical problem, and the possibility of drug-induced thrombocytopenia must be considered. Moreover, chemotherapy agents are known to typically cause thrombocytopenia by suppressing haematopoiesis, but they can also cause immune thrombocytopenia in which the mechanism involves antibody-mediated platelet destruction. CASE DESCRIPTION: We report a case of severe thrombocytopenia related to trastuzumab administration in which the patient exhibits a slow drift downward in platelet counts with repeated cycles of trastuzumab. A 70-year-old woman received a diagnosis of breast cancer and was treated with trastuzumab. She was confirmed to have a severe trastuzumab-induced thrombocytopenia after the 4th cycle. Retreatment with trastuzumab was not attempted. WHAT IS NEW AND CONCLUSION: Considering that trastuzumab is being increasingly used and that severe thrombocytopenia is a potentially life-threatening complication, its association must be seriously considered.
